Alterity Therapeutics Limited (ASX:ATH)
Australia · Delayed Price · Currency is AUD 0.0110
+0.0010 (10.00%)
May 8, 2026, 4:10 PM AEST
Alterity Therapeutics Company Description
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia.
The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease.
It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019.
Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Alterity Therapeutics Limited
| Country | Australia |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | David Stamler |
Contact Details
Address: 350 Collins Street Melbourne, VIC VIC Australia | |
| Phone | 61 3 9349 4906 |
Stock Details
| Ticker Symbol | ATH |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000043945 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David A. Stamler M.D. | Chief Executive Officer and Director |
| Abby Macnish Niven B.Com., B.Sc., C.F.A. | Chief Financial Officer and Company Secretary |
| Dr. Rudolph Emile Tanzi Ph.D. | Chief Scientific Advisor and Member of Research and Development Advisory Board |
| Dr. Steven D. Targum M.D. | Chief Medical Advisor |
| Dr. Robert Cherny | Head of Research |